Why This AMD Analyst Is Bumping Up Price Target For Stock By 19% Following Q4 Results
Advanced Micro Devices Inc.
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
ACM Research Likely To Gain From China’s Mature Node Investment, DRAM Spend, Analyst Says
Needham analyst Quinn Bolton maintained ACM Research Inc (NASDAQ:ACMR) with a Buy and raised the price target from $10 to $12. Bolton…
Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…
Harmonic Likely To See Upside After Securing Comcast Deal And Emerges As Front-Runner For Charter Win, Analysts Say
Needham analyst Ryan Koontz reiterated Harmonic Inc (NASDAQ:HLIT) with a Buy and maintained a $19 price target. HLIT reported a strong 4Q22.…
Truist Financial Analyst Downgrades Stock Citing Growing Deposit Competition, Unlikeliness Of Debt Recovery
Stephens & Co analyst Terry McEvoy downgraded Truist Financial Corp (NYSE:TFC) from Overweight to Equal-Weight and a $53 price target. On average,…
InVitae’s ‘Long, Uncertain Path’ Toward Profitability: Analyst Downgrades Biotech
Shares of Invitae Corp (NYSE: NVTA) came under pressure on Monday, after gaining more than 24% in January.
Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs.
Amid Challenges, Analyst Advises Investors To Build Positions: Cannabis Is A Real Industry With $26Bn In 2022 Sales
One of the biggest struggles the cannabis industry still faces is the lack of financial services. Under existing federal law, financial institutions are not allowed to provide their services to marijuana businesses even in states with legal cannabis programs.
Peloton To See Subdued Demand In Q2, Says Analyst
Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on the shares of Peloton Interactive Inc (NASDAQ:PTON) with a price target…